Top Research in Lupus Presented at ACR Convergence 2020

Abstract 1824—Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate, NKTR-358

Dr. Pisetsky: This study evaluated the effects of administration of a polyethylene glycol (PEG) conjugate of a recombinant human IL-2 molecule on T regulatory (Treg) cell numbers. Increasing Treg cells has the potential to downregulate autoimmune responses and, thus, represents a novel treatment approach. The agent in question, NKTR-358, differs from native IL-2 in the nature of receptor binding and duration of biological activity. As the data indicated, NKTR-359 can produce a dose dependent increase in the population of regulatory cells known as CD25^bright Tregs. Because this agent did not increase CD4+ or CD8+ conventional T cell numbers, this strategy may have clinical utility.

Visit the ACR’s Meeting Abstracts site for more research presented at ACR Convergence 2020.

[Back to the Resource Center.]